- Mesoblast ( NASDAQ: MESO ) stock fell ~10% on Tuesday after Jefferies Financial Group downgraded the shares to Hold from Buy, with an unchanged price target of A$1.25, citing recent share price outperformance.
- The SA Quant Rating on the shares is Hold , the rating is in contrast to the average Wall Street Analysts' rating of Buy . YTD, the stock has fallen ~33% , see chart here .
- Analyst David Stanton noted that he continues to value the Australian company's late-stage pipeline at A$1.25 and made no changes to his forecast and timelines for approval of Mesoblast's main opportunities.
For further details see:
Mesoblast stock falls 10% as Jefferies cuts rating to Hold